Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Apr 24, 2019
Twitter (TWTR, $39.76) crushes Q1 earnings expectations, and reports higher-than-expected user count

Twitter (TWTR, $39.76) crushes Q1 earnings expectations, and reports higher-than-expected user count

Twitter’s first quarter earnings turned out to be more than double of what analysts’ expected.

The social networking company’s adjusted earnings for the quarter came in at 37 cents per share, compared to analysts’ estimate of 15 cents (based on a Refinitiv survey).  

The company’s quarterly revenue of $787 million exceeded analysts’ expectations of $776.1 million (based on Refinitiv data).

Twitter’s count of monthly active users (MAUs), excluding SMS users, came in at 330 million, surpassing the 318 million figure expected in a FactSet consensus estimate (as reported by CNBC).

As for monetizable Daily Active Users (mDau), Twitter reported an average figure of 134 million for the first quarter, which is a major increase from 120 million a year earlier. In the U.S. alone, Twitter had 28 million average mDAUs for the first quarter, compared with 26 million in the year-ago quarter. The company defines mDAU as “Twitter users who log in and access Twitter on any given day through Twitter.com or our Twitter applications that are able to show ads”.

Looking ahead, Twitter forecasts that its second-quarter revenue would range between $770 million to $830 million, compared with analysts’ estimates of $783.9 million to $853.6 million in the Refinitiv survey. The company reaffirmed that it expects cash operating expenses to increase about 20% year over year in 2019, owing to its investments in areas like health, conversation, revenue product and sales, and platform.

In recent times, the company has emphasized that it is taking proactive steps to curb abuse and hate speech on its platform.

 

 

 

 

 

Related Ticker: TWTR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Related Portfolios: TECHNOLOGY ETFs
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a global platform for public self expression and conversation in real time

Industry InternetSoftwareServices

Profile
Details
Industry
Internet Software Or Services
Address
1355 Market Street
Phone
+1 415 222-9670
Employees
7500
Web
https://www.twitter.com
Interact to see
Advertisement
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.